Norwegian radiopharmaceutical company announces successful closing of a private placement that will allow the company to initiate the next phase of clinical development of its lead product candidate Radspherin®
Norwegian radiopharmaceutical company is contemplating a private placement to raise funds for the phase 2A development of it’s lead product candidate Radspherin®
7MBq dose of Radspherin® determined to be safe, and approved by the SMC as the recommended clinical dose for repeated injection and expansion cohorts of RAD-18-002 study
Safety Monitoring Committee review of second dose-level cohort allows advancement of Phase 1 RAD-18-001 study to third cohort dose level cohort
Safety Monitoring Committee review of third dose-level cohort allows progression of Phase 1 RAD-18-002 study to fourth and final cohort dose level cohort
Safety Monitoring Committee review of first dose-level cohort allows progression of RAD-18-001 study to second dose level cohort
Safety review of second dose-level cohort allows study to advance to third cohort of colorectal cancer patients with peritoneal carcinomatosis in Radspherin® clinical trial.
Safety review of first dose-level cohort allows progression to second cohort of colorectal cancer patients with peritoneal carcinomatosis in Radspherin® clinical trial.
Radiopharmaceutical company starts first-in-human trial in a second patient population; ovarian cancer patients suffering from peritoneal carcinomatosis Oncoinvent AS, a clinical stage radiopharmaceutical company developing novel radioisotope-based therapies to provide new therapeutic options for cancer patients, today announced that a second phase 1 clinical trial of it’s lead candidate compound Radspherin® has been initiated. The first ovarian cancer patient has been treated with Radspherin® at the Radium Hospital in Oslo under the guidance of clinical investigator Dr. Yun Wang, M.D., Ph.D.
Reference is made to the extraordinary general meeting notice published on 20th of May 2020 regarding a repair issue with gross proceeds of up to NOK 9 million directed towards eligible shareholders and company employees (the “Repair Issue”). The Repair Issue consisted of an offer of minimum 1 and maximum 175,000 new shares (each an “Offer Share”) in Oncoinvent AS to eligible shareholders and an offer of minimum 1 and maximum 25,000 new shares (each an “Offer Share”) in Oncoinvent AS to eligible employees. The subscription period for the Repair Issue ended on 29th of May 2020 at 16.30 hours (CEST). The subscription price in the Repair Issue was NOK 45 per Offer Share.